News

Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies

Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies, which might mean the therapy can work even when IPF is linked to an autoimmune disease, a study suggests. The study, “Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according…

Cedars-Sinai, Rubedo Partner to Develop Targeted IPF Treatments

Rubedo Life Sciences announced that it has partnered with Cedars-Sinai Medical Center, also in California, to advance its idiopathic pulmonary fibrosis (IPF) program and conduct collaborative research. The biopharmaceutical’s IPF program focuses on developing senolytics, or small molecules that target harmful senescent cells. These cells increase inflammation, fibrosis…

Work Stops on Fezagepras, or PBI-4050, as Potential IPF Treatment

Liminal BioSciences is stopping the clinical development of its investigative oral therapy fezagepras (PBI-4050) for idiopathic pulmonary fibrosis (IPF), based on interim pharmacological data from a Phase 1 clinical trial testing it at ascending doses in healthy volunteers. The decision comes less than a month after the company announced plans…

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who…

Failed HIV Therapy May Combat COVID-19-induced PF

An experimental therapy that proved ineffective in treating HIV infections now has shown promising potential at preventing or limiting pulmonary fibrosis (PF) caused by SARS-CoV-2, the virus that causes COVID-19. That finding, from a mouse model of induced PF, was detailed in the study  “Targeting RUNX1…